324 related articles for article (PubMed ID: 36161291)
21. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
23. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG; Patel RP; Ruella M; Barta SK
Transplant Cell Ther; 2024 Feb; 30(2):171-186. PubMed ID: 37866783
[TBL] [Abstract][Full Text] [Related]
24. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
[TBL] [Abstract][Full Text] [Related]
26. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
[TBL] [Abstract][Full Text] [Related]
27. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
Huang R; Wen Q; Zhang X
J Hematol Oncol; 2023 Apr; 16(1):35. PubMed ID: 37029381
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
Tanaka J
Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Strati P; Gregory T; Majhail NS; Jain N
JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
[TBL] [Abstract][Full Text] [Related]
30. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations.
Wang L
Curr Res Transl Med; 2022 Jan; 70(1):103320. PubMed ID: 34768218
[TBL] [Abstract][Full Text] [Related]
31. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
[TBL] [Abstract][Full Text] [Related]
32. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
Roex G; Feys T; Beguin Y; Kerre T; Poiré X; Lewalle P; Vandenberghe P; Bron D; Anguille S
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32102267
[TBL] [Abstract][Full Text] [Related]
35. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
36. Challenges and optimal strategies of CAR T therapy for hematological malignancies.
Zhang Y; Xu Y; Dang X; Zhu Z; Qian W; Liang A; Han W
Chin Med J (Engl); 2023 Feb; 136(3):269-279. PubMed ID: 36848181
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
38. [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].
Zhu XY; Liu X; Wang XB; Wang AY; Wang M; Liu NN; You FT; Pan GF; Yang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1367-1375. PubMed ID: 32798428
[TBL] [Abstract][Full Text] [Related]
39. CAR-T treatment for hematological malignancies.
Atrash S; Bano K; Harrison B; Abdallah AO
J Investig Med; 2020 Jun; 68(5):956-964. PubMed ID: 32200355
[TBL] [Abstract][Full Text] [Related]
40. Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.
Cao X; Jin X; Zhang X; Utsav P; Zhang Y; Guo R; Lu W; Zhao M
Curr Treat Options Oncol; 2023 Mar; 24(3):184-211. PubMed ID: 36701037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]